TLDR
- DFTX stock surged over 13% in premarket trading after President Trump signed an Executive Order backing psychedelic drug research for mental health treatment
- The order pushes the FDA to accelerate research and approval of psychedelic treatments for disorders including suicide prevention
- Definium’s CEO publicly praised the order, highlighting their DT120 program targeting GAD and MDD
- DFTX has gained 300%+ over the past 12 months and hit a 52-week high of $25.63
- Wall Street holds a Strong Buy consensus with an average price target of $38.75 — about 70% upside from current levels
Definium Therapeutics stock jumped on Monday after President Donald Trump signed an Executive Order aimed at speeding up research into psychedelic drugs as treatments for mental health conditions.
BREAKING: President Trump announces historic reforms to accelerate access to new medical research and treatments based on psychedelic drugs.
Trump will sign an executive order directing the FDA to expedite their review of certain psychedelics already designated as breakthrough… pic.twitter.com/16QIo6Fwbt
— Fox News (@FoxNews) April 18, 2026
The order specifically pointed to the potential of psychedelics to treat disorders including depression, anxiety, and suicidal ideation. It also called on the FDA to remove barriers slowing down that research.
DFTX was up 13.71% in premarket trading. The stock has now gained over 300% in the past 12 months, and hit a fresh 52-week high of $25.63 earlier in the session.
Definium’s CEO Rob Barrow came out swinging in response. He said the company “applauds the Administration’s recognition that psychedelic medicines may represent meaningful new treatment options.” Barrow pointed to their lead candidate, DT120, a lysergide tartrate being developed for Generalized Anxiety Disorder and Major Depressive Disorder.
The Executive Order also put a spotlight on veteran suicides, noting roughly 6,000 occur each year in the U.S. Suicide rates also climbed during COVID-era lockdowns, nearly matching a previous peak. The order framed psychedelic medicine as a potential tool to address both issues.
Despite the strong premarket move, actual trading volume was light. Only around 146,000 shares changed hands by the time of writing, against a three-month daily average of about 1.68 million.
Analyst Ratings and Price Targets
Wall Street is firmly behind this one. DFTX carries a Strong Buy consensus based on 12 Buy ratings over the past three months. The average price target sits at $38.75, which would represent roughly 70% upside from current levels.
Stifel initiated coverage earlier with a Buy rating, citing a high probability of success for DT120 in GAD. Piper Sandler also started coverage at Overweight, calling DT120 a “best-in-class opportunity” in the neuroplastogen space.
Phase 3 data for DT120 in GAD is expected in early Q3 2026. Earnings are also due in approximately 17 days.
Market Context
Generalized Anxiety Disorder affects more than 1 in 10 U.S. adults over a three-year period, according to a study in the Journal of Mood and Anxiety Disorders. GAD prevalence in the U.S. reached 6.6% in 2023.
DFTX stock is up 69.38% year-to-date and carries a market cap of around $2.26 billion.
InvestingPro data notes the stock may be undervalued based on Fair Value estimates, though the RSI currently points to overbought territory. The stock’s beta of 2.56 flags it as highly volatile.
The stock’s 52-week low was $5.45. It is currently trading near $25.78.
???? Our April Stock Picks Are Live!
A new month means new opportunities. Our analysts have just released their top stock picks for April, highlighting companies with strong momentum that rank highly on our KO Score algorithm. We’re also now sharing trade ideas for both long-term and short-term investors, giving you more ways to spot potential opportunities in the market.
Sign up to Knockout Stocks today and get 50% off to unlock the full list and see which stocks made the cut.
Use coupon code Special50 for your exclusive discount!
